Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06951724

Coronary Aspiration Catheter Clinical Trial

To evaluation of the efficacy and safety of an aspiration catheter in patients undergoing PCI for acute ST-segment elevation myocardial infarction (STEMI).

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Zhongshan Hospital, Fudan University

Shanghai, Shanghai Municipality, 200000, China

Location status: Recruiting

Location contact

Ge Junbo, Ph.D

CONTACT

[email protected]

021-31587871

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • General inclusion criteria
  • Age 18-80 years old (inclusive);
  • Clinical diagnosis of acute ST-segment elevation myocardial infarction (STEMI) within 24 hours of the onset of the disease (where ST-segment elevation is defined as ST-segment elevation of ≥1mm or 0.1mV in 2 or more consecutive leads of the 12-lead ECG);
  • Voluntary participation and signed written informed consent. Imaging Inclusion Criteria
  • DSA image showed that the target lesion was in situ coronary artery lesion;
  • Target vessel TIMI thrombus load classification ≥ grade 3 and TIMI flow classification ≤ grade 1;

Exclusion criteria

  • General exclusion criteria
  • previous PCI intervention or coronary artery bypass grafting (CABG) in the target vessel;
  • Comorbid cardiogenic shock;
  • severe renal failure or ongoing dialysis;
  • severe coagulation abnormalities (e.g., hypercoagulability due to blood disorders);
  • Failure of preoperative thrombolysis requiring remedial PCI;
  • Serious bleeding events requiring transfusion therapy within 30 days prior to surgery;
  • Ischemic stroke within 3 months prior to surgery;
  • Known allergy to anticoagulant and antiplatelet agents or contrast media;
  • female subjects who are known to be pregnant or lactating;
  • Participation or planned participation in other clinical studies of drugs or devices;
  • other conditions that the investigator evaluates to be unsuitable for participation in this trial.

Imaging exclusion criteria

  • Prognostic aspiration catheter needs to pass through the original stent mesh to reach the thrombus aspiration site;
  • severe calcification or tortuosity of the target vessel or extreme angulation that would interfere with the passage of the suction catheter;
  • the presence of an unprotected left main lesion (more than 50% narrowing of the lumen diameter);
  • the presence of severe triple coronary artery lesions requiring revascularization.

Treatment and study plan

Aspiration Catheter

Device

Thrombus aspiration using Aspiration Catheter

Export Advance Aspiration Catheter

Device

Thrombus aspiration using Export Advance Aspiration Catheter

Primary outcomes

  1. The rate of TIMI flow grad 3 after PCI

    Time frame: Immediately after procedure

    Defined as the percentage of subjects with TIMI flow graded 3 after PCI.

Secondary outcomes

  1. TIMI flow after PCI

    Time frame: Immediately after procedure

    Target vessel TIMI (Thrombolysis In Myocardial Infarction) flow grad after PCI, after completion of of coronary thrombus using the test device or control device to complete thrombus aspiration

  2. MBG

    Time frame: Immediately after procedure

    MBG (Myocardial Blush Grade) after coronary thrombus aspiration using either the test device or the control device. There are 4 levels of MBG. Grades range from 0 and up to 3, with higher grades being better.

  3. TIMI Thrombus Grade

    Time frame: Immediately after procedure

    TIMI Thrombus Grade after coronary thrombus aspiration using either the test device or the control device. There are 6 levels of MBG. Grades range from 0 and up to 5, with higher grades being worse.

  4. STR(ST-segment resolution) at 90 minutes

    Time frame: Day 0

    The index of change in the highest level of ST-segment elevation relative to the highest level of preoperative ST-segment elevation was assessed on the basis of electrocardiographic at 90 min ± 30 min after PCI.

  5. Thrombus aspiration time and number of aspirations

    Time frame: Immediately after procedure

    Record and compare the total thrombus aspiration time and number of aspirations in both groups.

  6. Device technical success rate

    Time frame: Immediately after procedure

    The test device or control device is able to successfully pass through all target lesions, complete thrombus aspiration, and successfully withdraw without complications relate to the procedure during thrombus aspiration, and TIMI flow grade 3 in the immediately after PCI.

  7. MACE

    Time frame: 30-day follow-up after procedure

    MACE includes cardiovascular death, recurrent myocardial infarction, all strokes, and target vessel revascularization (TVR)

  8. AE and SAE

    Time frame: 30-day follow-up after procedure

    Incidence of all adverse events, serious adverse events in both groups

Study contacts

Contact information is provided by the study sponsor or research team.

Ge Junpo, Ph.D

CONTACT

[email protected]

021-31587851

Sponsors and collaborators

Lead sponsor

BrosMed Medical Co., Ltd

Industry

Registry information

Official study title

A Prospective, Multicenter, Randomized Controlled, Noninferiority Clinical Trial Evaluating the Efficacy and Safety of an Aspiration Catheter in Patients Undergoing PCI for Acute ST-Segment Elevation Myocardial Infarction (STEMI)

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Apr 30, 2025
Registry last updated
Apr 30, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.